Related Experiment Videos
New diagnostic inroads in hypertension and atherosclerosis
1Cardiovascular Division, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Insights
Hypertension treatment is shifting from broad blood pressure reduction to personalized monitoring. New imaging technologies enable early detection of cardiovascular changes, improving patient treatment selection.
Area of Science:
- Cardiology
- Medical Technology
- Hypertension Management
Background:
- Traditional hypertension management relied on reducing blood pressure, assuming decreased morbidity and mortality.
- Older clinical trials, forming the basis of this practice, predated modern antihypertensives like ACE inhibitors and calcium-channel blockers.
- Limitations existed in noninvasive methods for monitoring end-organ damage from hypertension.
Purpose of the Study:
- To highlight the limitations of past hypertension treatment strategies.
- To introduce the potential of advanced noninvasive technologies in cardiovascular monitoring.
- To advocate for personalized treatment selection in hypertension management.
Main Methods:
- Review of historical hypertension treatment practices and clinical trial limitations.
- Discussion of advancements in high-resolution ultrasound technology.
- Exploration of evolving magnetic resonance imaging (MRI) capabilities for cardiovascular assessment.
Main Results:
- Past treatment approaches may not be universally optimal due to outdated trial data.
- High-resolution ultrasound and MRI offer new avenues for early detection of cardiovascular changes.
- These technologies facilitate monitoring disease progression and regression.
Conclusions:
- Personalized medicine in hypertension requires monitoring end-organ effects.
- Advanced imaging technologies are crucial for tailoring treatment programs.
- The future of hypertension management involves individualized, technology-driven care.
Abstract:
In the past two to three decades, the practice among hypertension specialists has been to lower blood pressure with the strong assumption that morbidity and mortality would be reduced. This was largely based on large clinical trials done in the 1960s and 1970s that did not include angiotensin-converting enzyme inhibitors or calcium-channel blockers. Performing large clinical trials is expensive and the results often do not apply to individual patients. Until recently, noninvasive methods to monitor end-organ effects of elevated blood pressure and other cardiovascular risk factors were limited. The development of high-resolution ultrasound and evolving magnetic resonance technology will allow early detection of heart and blood vessel changes and will make monitoring of the progression and regression of disease possible. This will allow better selection of treatment programs for each patient.